# Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

> **NCT00225901** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kyoto University, Graduate School of Medicine** · enrollment: 16 (—)

## Conditions studied

- Liver Failure, Acute

## Interventions

- **DRUG:** Recombinant human hepatocyte growth factor

## Key facts

- **NCT ID:** NCT00225901
- **Lead sponsor:** Kyoto University, Graduate School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 16 (—)
- **Last updated:** 2005-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225901, "Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00225901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*